 REDWOOD CITY, Calif., Oct. 13, 2021 GLOBE NEWSWIRE -- Rezolute, Inc. Nasdaq: RZLT Rezolute or the Company, a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the pricing of an underwritten public offering of 6,030,847 shares of its common stock at a public offering price of 6.50 per share and of pre-funded warrants to purchase 1,661,461 shares of its common stock at a public offering price of 6.49 per pre-funded warrant, which represents the per share public offering price for the common stock less the 0.01 per share exercise price for each pre-funded warrant. 